Post-COVID-19 pulmonary fibrosis: An ongoing concern
Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae includi...
Main Author: | Nuha Nasser Alrajhi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
Series: | Annals of Thoracic Medicine |
Subjects: | |
Online Access: | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2023;volume=18;issue=4;spage=173;epage=181;aulast=Alrajhi |
Similar Items
-
Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
by: Hiroaki Ogata, et al.
Published: (2021-05-01) -
Identification and analysis of ongoing registered clinical intervention trials on COVID-19
by: Luis Armando Solano-Sandí, et al.
Published: (2020-10-01) -
Molecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19
by: Emma J. Kooistra, et al.
Published: (2023-08-01) -
COVID-19: A review of the ongoing pandemic
by: Pooja Pande, et al.
Published: (2020-01-01) -
Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection
by: Mousa Ahmad Alhiyari, et al.
Published: (2021-01-01)